Investors' Chronicle How to pass on wealth, AstraZeneca & Ceres: The Companies and Markets Show
Oct 3, 2025
Julian Hofmann, a seasoned pharmaceuticals expert, shares insights on AstraZeneca's potential blockbuster breast cancer drug, Enhertu, and the company’s strategic shifts. Val Cipriani, a business journalist, discusses the 'Great Wealth Transfer' and offers advice on gifting and inheritance tax, emphasizing planning for family wealth. Finally, Mark Robinson analyzes Ceres Power's disappointing interim results, Bosch’s exit, and the company's pivot toward growing tech markets, specifically data centers. Tune in for valuable insights!
AI Snips
Chapters
Transcript
Episode notes
US Voluntary Drug Deals Calm Markets
- The US administration's voluntary drug deals reduced immediate tariff and pricing fears for pharma investors.
- Markets rewarded Pfizer and AstraZeneca with double-digit rallies as uncertainty eased.
Enhertu Could Become A Major Blockbuster
- AstraZeneca's Enhertu received priority FDA review to become first-line metastatic breast cancer therapy.
- That status could push annual sales well past $5bn and solidify AstraZeneca's oncology growth story.
Astra Harmonises Listings To Access US Capital
- AstraZeneca will convert US ADRs to full shares while keeping UK headquarters and Stockholm listing.
- The move reflects where its commercial and capital opportunities primarily lie: the US market.